Nuwellis, Inc. (NUWE): Results of Operations and Financial Condition
Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20080204_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE August 13, 2026 Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin Recent capital raise and warrant exercis
How this was made
The 30-second read
Why it matters
Traders can reassess NUWE’s near-term liquidity risk (cash runway through Q2 2027 per the release), profitability trajectory (gross margin jump), and regulatory momentum (Aquadex label expansion advanced to a lower patient weight threshold).
Market read
The combination of revenue growth, a large gross margin improvement, and disclosed capital raises that extend runway can move NUWE’s risk premium ahead of the scheduled call.
What to watch
The article does not provide detailed guidance for future quarters, and the Aquadex label expansion is a pre-submission step rather than an approval, which can limit how far the market extrapolates.
Background
This is an SEC 8-K (Item 2.02) with an attached earnings release covering Q2 2026 financial results and business highlights for Nuwellis and its Aquadex SmartFlow system.
Ticker impact
Nuwellis reported Q2 2026 results, including 76% gross margin, $2.0M net sales, and cash of about $3.9M after financing.
Likely positive bias on open given gross margin expansion and disclosed cash runway extension through Q2 2027, but volatility risk remains due to continued losses and dilution-related warrant expense.
Key disclosed items are directionally supportive (revenue growth, large gross margin improvement, $12.7M gross proceeds raised, FDA pre-sub meeting outcome) but the company still reports a net loss and provides no forward guidance beyond runway extension.
Market effects
Highlights ongoing commercialization and manufacturing transition benefits for medical device makers, with margin improvement tied to pricing and contract manufacturing.
Primarily US-focused revenue growth and FDA label expansion progress, with limited direct regional spillover.
International revenue is described as lower, suggesting the near-term story is US execution rather than global demand acceleration.
Counterpoint
Gross margin improvement may be partly accounting and mix-driven, and the financing and warrant valuation expense underscore ongoing capital needs.
Key entities
- companyNuwellis, Inc.
Nasdaq-listed medical technology company reporting Q2 2026 results, financing proceeds, and Aquadex label expansion progress.
- productAquadex SmartFlow System
Continuous ultrafiltration therapy system; the company advanced proposed label expansion to patients weighing 5 kg or more after an FDA pre-submission meeting.
- executiveMike McCormick
Appointed President and Chief Executive Officer effective June 30, 2026.
